SRS16-86
Modify Date: 2025-08-27 11:55:21
SRS16-86 structure
|
Common Name | SRS16-86 | ||
|---|---|---|---|---|
| CAS Number | 1793052-96-6 | Molecular Weight | 432.558 | |
| Density | 1.3±0.1 g/cm3 | Boiling Point | 614.9±55.0 °C at 760 mmHg | |
| Molecular Formula | C26H32N4O2 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | 325.7±31.5 °C | |
Use of SRS16-86SRS16-86 is a potent inhibitor of ferroptosis[1]. SRS16-86 is more stable than more stable to metabolism and plasma than Ferrostatin-1 in vivo. SRS16-86 can be used for renal ischemia-reperfusion injury (IRI) and spinal cord injury (SCI) research[2][3]. |
| Name | SRS16-86 |
|---|---|
| Synonym | More Synonyms |
| Description | SRS16-86 is a potent inhibitor of ferroptosis[1]. SRS16-86 is more stable than more stable to metabolism and plasma than Ferrostatin-1 in vivo. SRS16-86 can be used for renal ischemia-reperfusion injury (IRI) and spinal cord injury (SCI) research[2][3]. |
|---|---|
| Related Catalog | |
| In Vitro | SRS16-86 (1 µM; 24 hours; in the presence or absence of erastin) inhibits ferroptosis in HT-1080 cells and NIH 3T3 cells[2]. |
| In Vivo | SRS16-86 (intraperitoneal injection; 2 mg/kg; 15 min before the onset of surgery) protects mice from functional acute renal failure and structural organ damage after ischemia–reperfusion injury (IRI)[2]. SRS16-86 (intraperitoneal injection; 2 mg/kg; 4 weeks) combination therapy with [Nec-1+SfA] is superior in the prevention of renal IRI compared with the double-combination therapy with [Nec-1+SfA]. Addition of 16-86 reduces plasma levels of serum urea and serum creatinine in IRI mice model[2]. SRS16-86 (intraperitoneal injection; 15 mg/kg; once a day; 7 days) enhances functional recovery after SCI, it decreases the levels of proinflammatory cytokines and the inflammatory adhesion factor in injured spinal cord in rats[3]. Animal Model: Renal IRI model Dosage: 2 mg/kg; 15 min before the onset of surgery Administration: Intraperitoneal injection; 2 mg/kg; 15 min before the onset of surgery Result: Was protective from renal IRI. Animal Model: Renal IRI model Dosage: 2 mg/kg Administration: Combination with Necrostatin-1/Sanglifehrin A; 2 mg/kg; 4 weeks Result: Further increased the protective effect of [Necrostatin-1/Sanglifehrin A] combination therapy in renal IRI model. |
| References |
| Density | 1.3±0.1 g/cm3 |
|---|---|
| Boiling Point | 614.9±55.0 °C at 760 mmHg |
| Molecular Formula | C26H32N4O2 |
| Molecular Weight | 432.558 |
| Flash Point | 325.7±31.5 °C |
| Exact Mass | 432.252533 |
| LogP | 4.93 |
| Vapour Pressure | 0.0±1.8 mmHg at 25°C |
| Index of Refraction | 1.656 |
| Benzoic acid, 3-[[(1Z)-5-pyrimidinylmethylene]amino]-4-(tricyclo[3.3.1.13,7]dec-1-ylamino)-, 1,1-dimethylethyl ester |
| 2-Methyl-2-propanyl 4-[(3s,5s,7s)-adamantan-1-ylamino]-3-[(Z)-(5-pyrimidinylmethylene)amino]benzoate |
| SRS16-86 |